Physician profile
John P Piper
NPI 1083775654
$1,446.71
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $350 · 2023: $24.85 · 2024: $46.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $258.21 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $213.11 | 2019 | |
| Janssen Biotech, INC. | $138.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $116.57 | 2019-2020 | |
| Janssen Products, Lp | $99.00 | 2019 | |
| Melinta Therapeutics, LLC | $85.83 | 2019-2020 | |
| Allergan, INC. | $78.88 | 2019-2020 | |
| Gilead Sciences, INC. | $78.83 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $78.32 | 2019-2020 | |
| Theratechnologies INC. | $55.23 | 2019-2020 | |
| Octapharma USA, INC. | $54.46 | 2020 | |
| Insmed, INC. | $37.68 | 2019 | |
| Nabriva Therapeutics, Plc | $30.33 | 2020 | |
| Abbvie INC. | $24.85 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.64 | 2024 | Livtencity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $21.81 | 2024 | Rebyota |
| Vyera Pharmaceuticals, LLC | $20.85 | 2019 | |
| Seqirus USA INC | $17.55 | 2019 | |
| Emd Serono, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.